EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes

Timothy C Chin-See-Chong, Jasper H Kappen, Elizabeth Palmer, Janice A Layhadi iD, Mohamed H Shamji, Johanna P M van der Valk iD

Clinical & Experimental Allergy · 2025-09 · 55 (9) · 773-783

DOI: 10.1111/cea.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 03.06.2025. Verfasst von Timothy C Chin-See-Chong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Asthma, Desensitization, Immunologic, Anti-Asthmatic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a complex, heterogeneous disease characterised by clinical phenotypes demonstrating distinct and overlapping immunological mechanisms, classified into type‐2 high and type‐2 low asthma endotypes. Both allergic and eosinophilic non‐allergic asthma are driven through an underlying type‐2 high‐endotype, which can be targeted using therapeutic approaches such as allergen‐specific immunotherapy (AIT) for allergic asthma and biologics. AIT demonstrates efficacy for the treatment of allergic asthma. Approved biologics for asthma management include using various interleukin antagonists and anti‐immunoglobulin E, with Tezepelumab offering promising treatments for both type‐2 high and type‐2 low asthma patients. Novel therapeutic candidates, such as Itepekimab and depemokimab, have demonstrated promising results in a Phase 2 clinical trial in moderate‐to‐severe asthma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaDesensitization, ImmunologicAnti-Asthmatic AgentsHumansPhenotypeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

allergen‐specific immunotherapyasthmabiologicsbiomarkersendotypephenotype

Substanzen

Anti-Asthmatic AgentsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK.
  • Department of Pulmonary Diseases, Erasmus Medical Centrum, Rotterdam, the Netherlands.

ORCID-Profile: Janice A Layhadi, Johanna P M van der Valk

Zitieren

APA

Chin-See-Chong, T. C., Kappen, J. H., Palmer, E., Layhadi, J. A., Shamji, M. H., & van der Valk, J. P. M. (2025). Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy, 55(9), 773-783. https://doi.org/10.1111/cea.70084

Vancouver

Chin-See-Chong TC, Kappen JH, Palmer E, Layhadi JA, Shamji MH, van der Valk JPM. Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes. Clinical & Experimental Allergy. 2025;55(9):773-783. doi:10.1111/cea.70084

BibTeX
@article{ChinSeeChong2025,
  author = {Chin-See-Chong, Timothy C and Kappen, Jasper H and Palmer, Elizabeth and Layhadi, Janice A and Shamji, Mohamed H and van der Valk, Johanna P M},
  title = {Mechanisms and Treatment of Type 2 High and Low Asthma Endotypes},
  journal = {Clinical & Experimental Allergy},
  year = {2025},
  volume = {55},
  number = {9},
  pages = {773--783},
  doi = {10.1111/cea.70084}
}
Kostenlos starten →